Literature DB >> 17360762

Highly variable neural involvement in sphingomyelinase-deficient Niemann-Pick disease caused by an ancestral Gypsy mutation.

Violeta Mihaylova1, Janina Hantke, Ivanka Sinigerska, Silvia Cherninkova, Margarita Raicheva, Sonja Bouwer, Radka Tincheva, Djako Khuyomdziev, Jaume Bertranpetit, David Chandler, Dora Angelicheva, Ivo Kremensky, Pavel Seeman, Ivailo Tournev, Luba Kalaydjieva.   

Abstract

Niemann-Pick disease (NPD), an autosomal recessive disorder resulting from mutations in the sphingomyelin phosphodiesterase 1 (SMPD1) gene, is subdivided into the acute, lethal neuronopathic type A, and the chronic visceral type B, explained by the different residual activity levels of acid sphingomyelinase (ASMase). An increasing number of reports on intermediate forms, challenging this traditional clinical classification, have described a broad range of neurological manifestations; however genotype-phenotype correlations have been compromised by relatively small sample sizes and/or allelic heterogeneity. Here we present a genetically homogeneous group of 20 Gypsy patients with intermediate NPD, where we observed a surprising diversity of neurological features. All affected subjects were homozygous for the same ancestral mutation, W391G in SMPD1, yet displayed the entire spectrum of phenotypic variation observed previously in unrelated affected subjects of diverse ethnicity and disease-causing mutations, ranging from subclinical retinal involvement to severe ataxia, cognitive deficits and psychiatric disorders. The clinical heterogeneity of W391G homozygotes points to additional factors, beyond SMPD1 and residual ASMase, which determine the localization, extent and severity of neural involvement. The phenotype similarity of affected relatives suggests a possible role of genetic modifying factors. In practical terms, W391 is common in the Gypsy population and the diagnosis of NPD should be borne in mind despite the atypical course of the disease. Generally, our findings indicate that mutation analysis is of limited value in predicting brain damage, and the option of enzyme replacement therapy should be considered in intermediate NPD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17360762     DOI: 10.1093/brain/awm026

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  16 in total

1.  Deficiency of sphingomyelin synthase-1 but not sphingomyelin synthase-2 causes hearing impairments in mice.

Authors:  Mei-Hong Lu; Makoto Takemoto; Ken Watanabe; Huan Luo; Masataka Nishimura; Masato Yano; Hidekazu Tomimoto; Toshiro Okazaki; Yuichi Oike; Wen-Jie Song
Journal:  J Physiol       Date:  2012-05-28       Impact factor: 5.182

2.  ANO10 c.1150_1151del is a founder mutation causing autosomal recessive cerebellar ataxia in Roma/Gypsies.

Authors:  Teodora Chamova; Laura Florez; Velina Guergueltcheva; Margarita Raycheva; Radka Kaneva; Hanns Lochmüller; Luba Kalaydjieva; Ivailo Tournev
Journal:  J Neurol       Date:  2011-10-19       Impact factor: 4.849

3.  Severe neuropsychiatric symptoms in two siblings with intermediate type of Niemann-Pick disease.

Authors:  V Mihaylova; J Hantke; S Cherninkova; S Krastev; M Radionova; M Raicheva; I Sinigerska; H Jelev; A Jablensky; L Kalaydjieva; I Tournev
Journal:  J Neurol       Date:  2008-07-14       Impact factor: 4.849

Review 4.  An update on inherited ataxias.

Authors:  Tanja Schmitz-Hübsch; Thomas Klockgether
Journal:  Curr Neurol Neurosci Rep       Date:  2008-07       Impact factor: 5.081

5.  Molecular genetic characterization of novel sphingomyelin phosphodiesterase 1 mutations causing niemann-pick disease.

Authors:  Beata Tóth; Melinda Erdős; Annamária Székely; László Ritli; Péter Bagossi; János Sümegi; László Maródi
Journal:  JIMD Rep       Date:  2011-09-27

6.  Epidemiological, clinical and biochemical characterization of the p.(Ala359Asp) SMPD1 variant causing Niemann-Pick disease type B.

Authors:  Mariana Acuña; Pablo Martínez; Carol Moraga; Xingxuan He; Mauricio Moraga; Bessie Hunter; Peter Nuernberg; Rodrigo A Gutiérrez; Mauricio González; Edward H Schuchman; José Luis Santos; Juan Francisco Miquel; Paulina Mabe; Silvana Zanlungo
Journal:  Eur J Hum Genet       Date:  2015-04-29       Impact factor: 4.246

7.  Characterization of common SMPD1 mutations causing types A and B Niemann-Pick disease and generation of mutation-specific mouse models.

Authors:  Iwan Jones; Xingxuan He; Fourogh Katouzian; Peter I Darroch; Edward H Schuchman
Journal:  Mol Genet Metab       Date:  2008-09-23       Impact factor: 4.797

8.  A prospective, cross-sectional survey study of the natural history of Niemann-Pick disease type B.

Authors:  Margaret M McGovern; Melissa P Wasserstein; Roberto Giugliani; Bruno Bembi; Marie T Vanier; Eugen Mengel; Scott E Brodie; David Mendelson; Gwen Skloot; Robert J Desnick; Noriko Kuriyama; Gerald F Cox
Journal:  Pediatrics       Date:  2008-07-14       Impact factor: 7.124

Review 9.  The pathogenesis and treatment of acid sphingomyelinase-deficient Niemann-Pick disease.

Authors:  E H Schuchman
Journal:  J Inherit Metab Dis       Date:  2007-07-12       Impact factor: 4.982

10.  Prospective study of the natural history of chronic acid sphingomyelinase deficiency in children and adults: eleven years of observation.

Authors:  Margaret M McGovern; Melissa P Wasserstein; Bruno Bembi; Roberto Giugliani; K Eugen Mengel; Marie T Vanier; Qi Zhang; M Judith Peterschmitt
Journal:  Orphanet J Rare Dis       Date:  2021-05-10       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.